Biodesix Inc (BDSX) - Net Assets
Based on the latest financial reports, Biodesix Inc (BDSX) has net assets worth $-1.72 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($88.72 Million) and total liabilities ($90.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Biodesix Inc to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.72 Million |
| % of Total Assets | -1.94% |
| Annual Growth Rate | N/A |
| 5-Year Change | -49.29% |
| 10-Year Change | N/A |
| Growth Volatility | 174.72 |
Biodesix Inc - Net Assets Trend (2018–2024)
This chart illustrates how Biodesix Inc's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Biodesix Inc to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Biodesix Inc (2018–2024)
The table below shows the annual net assets of Biodesix Inc from 2018 to 2024. For live valuation and market cap data, see Biodesix Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $20.88 Million | +355.81% |
| 2023-12-31 | $4.58 Million | -77.77% |
| 2022-12-31 | $20.61 Million | +4.46% |
| 2021-12-31 | $19.73 Million | -52.08% |
| 2020-12-31 | $41.17 Million | +118.01% |
| 2019-12-31 | $-228.54 Million | -15.41% |
| 2018-12-31 | $-198.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biodesix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26235900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $145.00K | 0.69% |
| Other Components | $483.23 Million | 2314.75% |
| Total Equity | $20.88 Million | 100.00% |
Biodesix Inc Competitors by Market Cap
The table below lists competitors of Biodesix Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DP POLAND PLC
F:2OP
|
$79.44 Million |
|
Ladprao General Hospital Public Company Limited
BK:LPH
|
$79.44 Million |
|
CAG Group AB (publ)
ST:CAG
|
$79.45 Million |
|
Rimbunan Sawit Bhd
KLSE:5113
|
$79.45 Million |
|
Azaria Rental SOCIMI S.A.
MC:YAZR
|
$79.42 Million |
|
Definitive Healthcare Corp
NASDAQ:DH
|
$79.40 Million |
|
Fortress Biotech Inc
NASDAQ:FBIO
|
$79.39 Million |
|
Orexo AB
ST:ORX
|
$79.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biodesix Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,580,000 to 20,876,000, a change of 16,296,000 (355.8%).
- Net loss of 42,931,000 reduced equity.
- Share repurchases of 625,000 reduced equity.
- New share issuances of 55,625,000 increased equity.
- Other factors increased equity by 4,227,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-42.93 Million | -205.65% |
| Share Repurchases | $625.00K | -2.99% |
| Share Issuances | $55.62 Million | +266.45% |
| Other Changes | $4.23 Million | +20.25% |
| Total Change | $- | 355.81% |
Book Value vs Market Value Analysis
This analysis compares Biodesix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.22x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-149.22 | $16.81 | x |
| 2019-12-31 | $-5.00 | $16.81 | x |
| 2020-12-31 | $8.51 | $16.81 | x |
| 2021-12-31 | $14.42 | $16.81 | x |
| 2022-12-31 | $9.79 | $16.81 | x |
| 2023-12-31 | $1.12 | $16.81 | x |
| 2024-12-31 | $3.22 | $16.81 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biodesix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -205.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -60.19%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 4.66x
- Recent ROE (-205.65%) is above the historical average (-279.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -128.06% | 0.52x | 0.00x | $-6.36 Million |
| 2019 | 0.00% | -125.15% | 0.59x | 0.00x | $-7.87 Million |
| 2020 | -76.16% | -68.81% | 0.38x | 2.94x | $-35.47 Million |
| 2021 | -218.78% | -79.18% | 0.72x | 3.86x | $-45.13 Million |
| 2022 | -317.61% | -171.27% | 0.41x | 4.51x | $-67.51 Million |
| 2023 | -1138.56% | -106.23% | 0.50x | 21.64x | $-52.60 Million |
| 2024 | -205.65% | -60.19% | 0.73x | 4.66x | $-45.02 Million |
Industry Comparison
This section compares Biodesix Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $726,267,829
- Average return on equity (ROE) among peers: -107.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biodesix Inc (BDSX) | $-1.72 Million | 0.00% | N/A | $79.44 Million |
| Agilent Technologies Inc (A) | $4.63 Billion | -22.30% | 0.77x | $35.96 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $976.24K | -188.19% | 0.03x | $6.13 Million |
| Applied DNA Sciences Inc (APDN) | $8.97 Million | -77.97% | 0.43x | $3.99 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.07 Million | 0.00% | 0.00x | $3.77 Million |
| Biocept Inc. (BIOCQ) | $8.86 Million | -362.16% | 2.48x | $525.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $480.11 Million | 1.55% | 0.32x | $4.36 Billion |
| Burning Rock Biotech Ltd (BNR) | $1.16 Billion | -83.85% | 0.37x | $63.90 Million |
| CareDx Inc (CDNA) | $261.33 Million | -72.81% | 0.79x | $1.13 Billion |
| Check Cap Ltd (CHEK) | $5.91 Million | -165.47% | 0.34x | $9.42 Million |
About Biodesix Inc
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also pro… Read more